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Purpose of the study
Data on the hepatic safety of TPV/r comes mostly from
clinical trials. The liver tolerability of TPV/r in real life
conditions of use could be different. However, there are
little data on this issue from clinical cohorts. Because of
these, we evaluated the incidence and risk factors of severe
liver events among HIV-infected patients treated with
drug combinations including TPV/r.
Methods
150 patients were selected because they started a regimen
that included TPV/r (500/200 mg BID), and had clinical
visits at least every 3 months. Patients who discontinued
TPV/r before their first visit were included.
Summary of results
Twelve (8%) individuals developed grade ≥3 transami-
nase elevation (G ≥ 3TE). Nine (6%) patients discontin-
ued TPV/r due to liver events. Six (8.6%) of 70 HCV-
coinfected patients and six (7.5%) of 80 subjects without
HCV co-infection developed G ≥ 3TE (p = 1). Liver fibrosis
was evaluable in 48 (63%) of 76 individuals with HBV
and/or HCV infection. Four (13%) of 30 subjects with
moderate-to-severe fibrosis and none of 18 with mild
fibrosis showed G ≥ 3TE (p = 0.3). None of nine patients
with cirrhosis showed G ≥ 3TE.
Conclusion
Liver tolerability of TPV/r was generally good in a cohort
of patients with a high proportion of HCV co-infection,
including subjects with advanced fibrosis. Monitoring of
liver enzymes was not different for co-infected patients.
Thus, more frequent blood testing does not seem war-
ranted for these patients.
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